摘要：智美新升 健康未来 2025年4月13-17日，以"智美新升，健康未来"为主题的2025年东森健康自然美AI科技美业全健康新品战 略发布会在浙江安吉、广西桂林双城耀启，这是东森健康自然美首次开展两地协同型新品战略发布会。 东森集团总裁王令麟先生、东森健康自然美CEO郑吉崇先生、东森健康自然美执行董事长王世均先生等 重磅嘉宾纷纷亮相，与全国上千家代理商共同见证"AI科技·美业·全健康"最新研发成果，创富领航美业 新征程。 AI科技美业全健康领航 双城联动千店集结 在国务院《关于促进服务消费高质量发展的意见》指导下，美业正成为扩大内需、推动消费升级的核心 引擎。而在工信部"十四五"智能制造规划引领下，美业以AI+生物科技突破行业边界，这种"硬科技+软 服务"模式，正是国家创新体系在消费领域的生动实践。正如东森健康自然美CEO郑吉崇所言，"我们要 洞察可能彻底改变未来生产结构的重要趋势，成为穿越周期的市场造风者。" 作为中国生态经济发展的 两大标杆，安吉和桂林不仅以差异化的资源描绘了"绿水青山"生态美学发展逻辑，还积极以AI科技为杠 杆，为经济智能化转型提供了"技术驱动"与"生态赋能"的双重样本。这与东森健康 ...

Financial Performance - Natural Beauty reported a revenue increase of 15% year-over-year, reaching HKD 1.2 billion for the fiscal year 2024[3]. - The company achieved a net profit margin of 12%, translating to a net profit of HKD 144 million, up from HKD 120 million in the previous year[3]. - Future guidance indicates expected revenue growth of 10-15% for 2025, with a target revenue of HKD 1.32 billion[3]. - The Group's revenue for 2024 increased by 5.2% to HK$353.7 million compared to HK$336.0 million in 2023, primarily driven by an increase in product sales of HK$18.5 million[25]. - Revenue from the PRC market rose by 7.3% from HK$237.8 million in 2023 to HK$255.2 million in 2024, while revenue from the Taiwan market increased by 8.7% to HK$92.1 million[26]. - The Group reported a loss before tax of approximately HK$105.2 million in 2024, compared to a loss of HK$11.9 million in 2023, reflecting a decrease in pre-tax profit margin[57]. - The Group's net loss increased significantly to approximately HK$103.6 million in 2024, compared to a net loss of approximately HK$15.1 million in 2023[65][70]. - The effective tax rate shifted from 27.3% in 2023 to -1.5% in 2024, with income taxation expenses changing from HK$3.2 million to a credit of HK$1.6 million[64][69]. - The Group's gearing ratio increased from 29.9% in 2023 to 43.0% in 2024, indicating a rise in financial leverage[67][72]. - The Group's projected revenue compound annual growth rate (CAGR) is estimated at 16.4% for the upcoming years, up from 14.7% in the previous year[58]. Market Expansion and Product Development - User engagement metrics showed a 20% increase in active users, totaling 500,000 by the end of 2024[3]. - The company plans to launch three new product lines in 2025, focusing on eco-friendly and sustainable beauty solutions[3]. - Market expansion efforts include entering two new Southeast Asian countries, projected to contribute an additional HKD 200 million in revenue[3]. - The company is investing HKD 50 million in R&D for new technologies aimed at enhancing product efficacy and user experience[3]. - A strategic acquisition of a local beauty brand is anticipated to be finalized in Q2 2025, expected to enhance market share by 5%[3]. - The Group launched 12 skincare products and 9 health supplements in 2024, generating HK$43.0 million in sales[88][91]. - The health food series achieved sales of HK$33.7 million in 2024, marking an 86.2% increase from HK$18.1 million in 2023[89][91]. - The company plans to introduce Exosome Technology into the Taiwan market to meet growing consumer demand, alongside the development of an AI Massage Robot to enhance service precision[99][104]. Sales and Revenue Channels - Product sales accounted for 99.1% of total revenue in 2024, amounting to HK$350.4 million, an increase of 5.6% from HK$331.9 million in 2023[31]. - Sales from e-commerce, TV shopping, and telemarketing channels decreased to HK$37.8 million, down HK$3.7 million from HK$41.5 million in 2023, accounting for 10.7% of total revenue[83][84]. - In 2024, the Group achieved HK$315.8 million in sales from franchised/self-owned spas, an increase of HK$21.3 million from HK$294.5 million in 2023, representing 89.3% of total revenue[82][84]. Corporate Governance - Corporate governance improvements have been made, with the establishment of a new audit committee to enhance financial oversight[3]. - The Board of Directors consists of eight members, including three executive directors, two non-executive directors, and three independent non-executive directors[136]. - The Board met a total of eight times during 2024, exceeding the minimum requirement of four meetings per year[139]. - The company has adopted a code of conduct for securities transactions by directors, which complies with the Model Code, with no reported incidents of non-compliance for the year ended December 31, 2024[154]. - The Company established a Board Independence Evaluation Mechanism to ensure strong independent judgment, with satisfactory results reported for the year[169]. Operational Challenges and Costs - Distribution and selling expenses as a percentage of revenue increased to 48.4% in 2024 from 42.3% in 2023, with total expenses rising by HK$28.8 million to HK$171.0 million[45][51]. - Total administrative expenses increased by HK$14.4 million to HK$80.4 million in 2024, with significant costs in staff and legal fees[46][51]. - Other income and gains decreased by 46.4% from HK$7.9 million in 2023 to HK$4.2 million in 2024, mainly from rental income, interest income, and government grants[44][50]. - The fair value loss on investment properties increased to HK$19.7 million in 2024 from HK$5.8 million in 2023[55]. Strategic Initiatives - The company is implementing a multi-channel sales strategy in Taiwan, focusing on health food and optimizing online brand exposure through live streaming[115][118]. - The company aims to enhance its international competitiveness by investing in high-end intelligent beauty equipment and driving industry upgrades through technological innovation[113]. - The establishment of operation centers in key provinces in the PRC is part of the strategy to strengthen local market penetration[116]. - The company is combining original store expansion mechanisms with a distributor system to enhance precise targeting and team expansion[116]. - The company is committed to enhancing brand building and expanding its comprehensive healthcare business territory by 2025[117].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Natural Beauty Bio-Technology Limited 自然美生物科技有限公司 （於開曼群島註冊成立之有限公司） （股份代號：00157） 截至二零二四年十二月三十一日止年度經審核全年業績公告 本 公 司 董 事 會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 的 經 審 核 業 績。本 公 告 載 有 本 公 司 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 年 報（「二零二四年年報」）全 文，符 合 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則 有 關 全 年 業 績 初 步 公 佈 隨 附 資 料 的 相 關 規 定。本 公 司 二 零 二 四 年 年 報 的印刷版將於二零二五年三月上旬或前後寄發予已選擇收取印刷版的本公司股 東。本 公 司 二 零 ...

INB 自然美 NATURAL BEAUT Natural Beauty Bio-Technology Limited 自然美生物科技有限公司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號 : 00157 2024 INTERIM REPORT 中期報告 Mission Statement 我們的使命 Natural Beauty is dedicated to cultivate our staff, customers, students and franchisees to appreciate our education, products and services, which are the mission and belief of the brand and to make modern ladies beautiful, confident and wealthy. 我們致力於使員工、顧客、學員及加盟老師們存著一份感恩的心來到自然 美，學習自然美容術及使 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Natural Beauty Bio-Technology Limited 自然美生物科技有限公司 （於開曼群島註冊成立之有限公司） （股份代號：00157） 截至二零二四年六月三十日止六個月之中期業績公告 自 然 美 生 物 科 技 有 限 公 司（「本公司」）董 事 會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 之 未 經 審 核 綜 合 業 績。本 公 告 載 有 本 公 司 截 至 二 零 二 四 年 六 月 三 十 日 止 年 度 中 期 報 告（「二零二四年中期報告」）全 文， 符合香港聯合交易所有限公司證券上市規則有關中期業績初步公佈隨附資料的 相 關 規 定。本 公 司 二 零 二 四 年 中 期 報 告 的 印 刷 版 將 於 二 零 二 四 年 八 月 寄 發 予 已 選 擇 收 取 印 刷 版 的 ...

Financial Performance - Revenue for FY2023 was HK$336,015,000, a slight increase from HK$335,880,000 in FY2022, representing a growth of 0.04%[14] - Gross profit for FY2023 was HK$200,345,000, compared to HK$189,130,000 in FY2022, indicating a growth of 5.8%[14] - Operating loss for FY2023 was HK$3,738,000, an improvement from the operating loss of HK$19,205,000 in FY2022[14] - Net loss for FY2023 was HK$15,111,000, compared to a net loss of HK$30,472,000 in FY2022, showing a reduction in losses by 50.5%[14] - Total assets as of FY2023 were HK$872,434,000, slightly up from HK$872,309,000 in FY2022[14] - Return on Equity (ROE) for FY2023 was -2.6%, an improvement from -5.1% in FY2022[14] - Return on Assets (ROA) for FY2023 was -1.7%, compared to -3.5% in FY2022, indicating better asset utilization[14] Dividends and Share Options - The company did not declare any dividends for FY2023, consistent with FY2022[14] - As of December 31, 2023, the Company had no share options granted, cancelled, or lapsed under the share option scheme[36] - The maximum number of shares available for grant under the share award schemes for the year ended December 31, 2023, was 60,006,027 shares[40] - No share awards were granted under the Share Award Schemes during the year ended December 31, 2023[41] - The share option scheme expired on May 12, 2021, and no new options have been issued since then[36] - The Company has adopted two share award schemes aimed at recognizing contributions and retaining key senior management[39] - The aggregate number of shares awarded under the share award schemes cannot exceed 10% of the relevant class of shares[39] - The aggregate number of new shares awarded under the scheme cannot exceed 3% of the issued share capital as of the Adoption Date[39] Employee and Compensation - As of December 31, 2023, the company employed a total of 479 employees, with 342 in mainland China, 119 in Taiwan, and 18 in other regions[57] - The total compensation for 2023 (excluding director remuneration) was approximately HKD 105,200,000, a decrease from HKD 124,700,000 in 2022[57] Corporate Governance - The company emphasizes strong corporate governance as a foundation for maximizing long-term returns to stakeholders[62] - The Audit Committee did not have any differing views from the Board regarding the selection and re-appointment of external auditors[100] - The company aims to continually review and enhance its corporate governance practices in line with local and international best practices[63] - Compliance manuals were provided to all Directors and senior management to ensure adherence to listing obligations[109] - The majority of the Audit Committee members are Independent Non-executive Directors, ensuring appropriate oversight[125] - New Directors receive comprehensive orientation training to understand their responsibilities and regulatory requirements[109] - The Company Secretary is responsible for keeping all Directors updated on Listing Rules and statutory requirements[109] Risk Management - The Internal Audit Department was established in early 2016 to enhance risk management and internal control systems, performing independent reviews of their adequacy and effectiveness[138] - The Company has developed various risk management procedures and guidelines for key business processes, including project management and financial reporting[134] - The Company conducts annual self-assessments to confirm compliance with control policies across all departments[139] - Management confirmed the effectiveness of the risk management and internal control systems to the Board and Audit Committee for the year ending December 31, 2023[170] - The Board is responsible for evaluating risks associated with achieving strategic objectives and maintaining effective risk management systems[164] Strategic Initiatives - The company aims to enhance its product offerings and expand its market presence in the coming years[18] - Future strategies include focusing on employee and customer engagement to foster brand loyalty and appreciation[18] - The company plans to launch an innovative "compound store" model in 2024, which will include new product offerings in beauty, health food, and high-end daily necessities, aimed at enhancing income amidst slow economic recovery[60] Shareholder Communication - The Company maintains an ongoing dialogue with shareholders through a dedicated Investor Relations section on its website[159] - The Company ensures clear communication with shareholders through various channels, including annual and interim reports[190] Board and Committee Activities - The Board of Directors met six times in 2023, exceeding the minimum requirement of four meetings per year[70] - The Nomination Committee held four meetings in 2023 to review the Board Diversity Policy and assess the independence of Independent Non-executive Directors[111] - The Audit Committee conducted six meetings in 2023, reviewing annual results for the year ended December 31, 2022, and interim results for the six months ended June 30, 2023[129] - The Remuneration Committee held two meetings during the year ended December 31, 2023, and reviewed proposed bonus awards for all employees and senior management[1] - The remuneration paid to the Group's auditors for audit services amounted to HK$2,159,000, with non-audit services for the review of interim results totaling HK$200,000[147] Securities Transactions - The Company did not purchase, sell, or redeem any of its listed securities during the year ended December 31, 2023[43] - No purchases, sales, or redemptions of the Company's listed securities were made by the Company or its subsidiaries during the year[47]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Natural Beauty Bio-Technology Limited 自然美生物科技有限公司 （於開曼群島註冊成立之有限公司） （股份代號：00157） 截至二零二三年十二月三十一日止年度經審核全年業績公告 本 公 司 董 事 會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 三 年 十 二 月 三 十 一 日 止 年 度 的 經 審 核 業 績。本 公 告 載 有 本 公 司 截 至 二 零 二 三 年 十 二 月 三 十 一 日 止 年 度 年 報（「二零二三年年報」）全 文，符 合 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則 有 關 全 年 業 績 初 步 公 佈 隨 附 資 料 的 相 關 規 定。本 公 司 二 零 二 三 年 年 報 的印刷版將於二零二四年三月上旬或前後寄發予已選擇收取印刷版的本公司股 東。本 公 司 二 零 ...

於二零二三年六月三十日，本集團合共僱用 429名僱員，其中302名派駐中國大陸，台灣有 111名，其他國家及地區則有16名。於截至二 零二三年六月三十日止六個月之總酬金約為 59,400,000港元（截至二零二二年六月三十止六 個月為73,500,000港元），其中包括退休福利相 關成本9,300,000港元（截至二零二二年六月三 十日止六個月為5,700,000港元）。截至二零二 三年六月三十日止六個月，並無產生認股權 開支（截至二零二二年六月三十日止六個月為 無）。為招聘、留聘及鼓勵表現卓越的僱員， 本集團保持並定期檢討具競爭力之酬金組合。 本集團與其僱員維持良好合作關係，並承擔彼 等的培訓及發展，更定期為本集團聘用之美容 師及加盟商提供專業培訓課程。 資本開支 本集團於截至二零二三年六月三十日止六個月 之資本開支為40,800,000港元，其主要包括中 國大陸新工廠建設23,600,000港元、新開店裝 修及設備17,100,000港元及辦公室裝修100,000 港元。 使用權資產和租賃負債 相關使用權資產及租賃負債主要位於中國大 陸及台灣。於二零二三年六月三十日，本集 團之使用權資產為33,800,0 ...

– 15 – | --- | --- | --- | --- | --- | |--------------------|------------|------------|----------|--------| | | | | | | | | 二零二三年 | 二零二二年 | | | | 按業務劃分之營業額 | 上半年 | 上半年 | 變 動 | | | | 千港元 | 千港元 | 千港元 | % | | 產 品 | | | | | | 中國大陸 | 109,985 | 94,329 | 15,656 | 16.6% | | 台 灣 | 40,039 | 60,004 | (19,965) | -33.3% | | 其 他 | 9,683 | 5,495 | 4,188 | 76.2% | | 總 計 | 159,707 | 159,828 | (121) | -0.1% | 服 務 中國大陸 1,500 3,319 (1,819) -54.8% 台 灣 – – – 0% 其 他 304 444 (140) -31.5% 總 計 1,804 3,763 (1,959) -52.1% 按業務劃分之 營業額 二 ...

Natural Beauty Bio-Technology Limited 自然美生物科技有限公司 (Incorporated in the Cayman Islands with limited liability) 《於開曼群島註冊成立之有限公司) Stock Code 股份代號 : 00157 Natural Beauty is dedicated to cultivate our staff, customers, students and franchisees to appreciate our education, products and services, which are the mission and belief of the brand and to make modern ladies beautiful, confident and wealthy. | --- | --- | --- | --- | --- | |----------------------------------------------------------------|----------------- ...